STAT

Revamped, bipartisan Senate package takes aim at drug prices — and props up other health programs, too

The bipartisan duo behind the revamped Senate drug pricing package has an interesting plan to build support: the reforms help offset the costs of other health priorities.
Sen. Chuck Grassley (R-Iowa)

WASHINGTON — Leaders of a key Senate committee unveiled a new version of a sweeping, bipartisan drug pricing bill Friday, and they’ve devised a novel plan to get it signed into law.

The bill hasn’t changed much from the version that was narrowly passed out of the Senate Finance Committee in July — though a handful of tweaks offer further benefits to seniors. Since then, however, the bill’s political prospects have grown brighter, particularly after key Trump administration officials endorsed it over a far more progressive proposal from House Speaker Nancy Pelosi.

Lawmakers have also devised a unique ploy to

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Sanders’ Pharma Pressure Campaign, AstraZeneca’s New ADC Factory, And More
Sen. Bernie Sanders is testing the limits of the powers of a Senate chairman with little hope of advancing his drug-pricing agenda legislatively.
STAT1 min read
Opinion: HHS’s Proposed Rule Pays Lip Service To Addressing The Climate Crisis, The Greatest Threat To Human Health
HHS's proposal for addressing the climate crisis serves as an example of what historian and philosopher Hannah Arendt defined as the "banality of evil."
STAT1 min read
STAT+: Pharmalittle: We’re Watching BIO Layoffs, AstraZeneca Plans To Double Revenue, And More
The Biotechnology Innovation Organization on Monday announced 30 layoffs that are part of a restructuring.

Related Books & Audiobooks